Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

@article{Honda2013AnticholestaticEO,
  title={Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.},
  author={Akira Honda and Tadashi Ikegami and M. Nakamuta and Teruo Miyazaki and Jun-ichi Iwamoto and Takeshi Hirayama and Yoshifumi Saito and Hajime Takikawa and Michio Imawari and Yasushi Matsuzaki},
  journal={Hepatology},
  year={2013},
  volume={57 5},
  pages={1931-41}
}
UNLABELLED Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC) that does not respond sufficiently to ursodeoxycholic acid (UDCA) monotherapy. The aim of this study was to explore the anticholestatic mechanisms of bezafibrate by analyzing serum lipid biomarkers in PBC patients… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
39 Citations
55 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…